Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature

Zhang, Yishi1; He, Wan1; Zhan, Ke2; Zhang, Luobin1; Cao, Hua1; Xu, Ruilian1

2023-05-16

10.3389/fonc.2023.1153233

FRONTIERS IN ONCOLOGY   影响因子和分区

2234-943X

Malignant mesothelioma that originates from mediastinal (MMM) is a rare form of malignant pleural mesothelioma (MPM). The prognosis of advanced stage MPM was poor, and the traditional treatment was chemotherapy. Here, we present a patient with MMM that was treated with anlotinib, a multitargeted tyrosine kinase inhibitor (TKI) who had a 24-month progression-free survival (PFS). Further review of the literature showed that, despite some explorations of applying small-molecule multitargeted TKIs in the treatment of MPM, until today, no large series had a positive result. Anlotinib had been approved by the China Food and Drug Administration on treating non-small cell lung cancer, soft tissue sarcoma, renal cell carcinoma, and medullary thyroid cancer. We assumed that the ability of anlotinib to target more tyrosine kinase receptors than most of other TKIs could contribute to the long duration of PFS in this case, but further study is needed to further validate the efficacy of anlotinib in treatment of MPM.

malignant mesothelioma tyrosine kinase inhibitor anlotinib malignant pleural mesothelioma mediastinal mesothelioma

SCI

英语

第一 ; 通讯

Oncology

Oncology

WOS:000998595100001

FRONTIERS MEDIA SA

Web of Science

1.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen Peoples Hosp, Jinan Univ,Southern Univ Sci & Technol,Dept Oncol,, Shenzhen, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen Peoples Hosp, Jinan Univ,Dept Spine Surg,Clin Med Coll 2, Shenzhen, Peoples R China

Zhang, Yishi,He, Wan,Zhan, Ke,et al. Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature[J]. FRONTIERS IN ONCOLOGY,2023,13.

Zhang, Yishi,He, Wan,Zhan, Ke,Zhang, Luobin,Cao, Hua,&Xu, Ruilian.(2023).Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature.FRONTIERS IN ONCOLOGY,13.

Zhang, Yishi,et al."Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature".FRONTIERS IN ONCOLOGY 13(2023).